Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK; C-100-21 Study Group.

J Clin Oncol. 2008 Feb 20;26(6):955-62. doi: 10.1200/JCO.2007.11.9941. Erratum in: J Clin Oncol. 2008 Aug 1;26(22): 3819.

PMID:
18281670
2.

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B; C-100-12 RCC Study Group.

Lancet. 2008 Jul 12;372(9633):145-54. doi: 10.1016/S0140-6736(08)60697-2. Epub 2008 Jul 3.

PMID:
18602688
3.

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.

Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C, Garbe C.

Cancer Immunol Immunother. 2011 Apr;60(4):487-93. doi: 10.1007/s00262-010-0957-3. Epub 2010 Dec 21.

PMID:
21174093
4.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G.

J Clin Oncol. 2002 Oct 15;20(20):4169-80. Erratum in: J Clin Oncol 2002 Dec 1;20(23):4610.

PMID:
12377960
5.

Vitespen: a preclinical and clinical review.

Wood CG, Mulders P.

Future Oncol. 2009 Aug;5(6):763-74. doi: 10.2217/fon.09.46. Review.

PMID:
19663726
6.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE.

J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.

7.

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.

Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N.

Br J Cancer. 2008 Apr 22;98(8):1336-41. doi: 10.1038/sj.bjc.6604266. Epub 2008 Mar 25.

8.

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.

di Pietro A, Tosti G, Ferrucci PF, Testori A.

Expert Opin Biol Ther. 2011 Oct;11(10):1395-407. doi: 10.1517/14712598.2011.605353. Epub 2011 Jul 30. Review.

PMID:
21801084
9.

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G.

Cancer Immunol Immunother. 2006 Aug;55(8):958-68. Epub 2005 Oct 8.

PMID:
16215718
10.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.

N Engl J Med. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.

11.

Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ.

Am J Clin Oncol. 2014 Jun;37(3):261-5. doi: 10.1097/COC.0b013e318277d5c8.

12.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.

J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.

13.

Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S.

Clin Cancer Res. 2011 Jul 1;17(13):4568-80. doi: 10.1158/1078-0432.CCR-11-0184. Epub 2011 May 17.

14.

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T.

Br J Cancer. 2004 Feb 23;90(4):773-80.

15.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

PMID:
23715572
16.

HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.

Tosti G, di Pietro A, Ferrucci PF, Testori A.

Expert Rev Vaccines. 2009 Nov;8(11):1513-26. doi: 10.1586/erv.09.108. Review.

PMID:
19863242
17.

Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited.

Randazzo M, Terness P, Opelz G, Kleist C.

Int J Cancer. 2012 May 15;130(10):2219-31. doi: 10.1002/ijc.27332. Epub 2012 Jan 24. Review.

18.

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.

Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A.

Ann Oncol. 2008 Jun;19(6):1195-201. doi: 10.1093/annonc/mdn001. Epub 2008 Feb 14.

19.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A.

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

PMID:
24019551
20.

Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.

Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19.

PMID:
19451711

Supplemental Content

Support Center